ReviewMolecular microbiology2017
Staphylococcus aureus biofilm: a complex developmental organism.
Review in Molecular microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 307 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
307 citing papers in PubMed, 524 citations in OpenAlex.
- Article
- Multifaceted Suppression of Staphylococcal Virulence Phenotypes: In Vitro Study of a Cellular Status With Reduced Agr Activity and Impaired Biofilm.MicrobiologyOpen · 2026Article
- Biofilm formation and dynamics in the marine cyanobacterium Prochlorococcus.Nature communications · 2026Article
- ImagingmBio · 2026Article
- Antibacterial and Antibiofilm Activity ofJournal of fungi (Basel, Switzerland) · 2026Article
- Staphylococcus aureus biofilms: molecular mechanisms, resistance determinants, and emerging therapeutic strategies.Molecular biology reports · 2026Review
- Virulence determinants and multidrug resistance profiles of biofilm-forming Staphylococcus aureus from healthy orthopedic surgical personnel.Antonie van Leeuwenhoek · 2026Article
- Lineage-Associated Genomic and Phenotypic Features of Bovine Mastitis-AssociatedMicroorganisms · 2026Article
- Human serum triglycerides promote Staphylococcus aureus biofilm formation and antibiotic tolerance.NPJ biofilms and microbiomes · 2026Article
- Virulence Profiling of Multidrug-Resistant ClinicalMicrobial drug resistance (Larchmont, N.Y.) · 2026Article
- Stage-Dependent Antibiofilm Effects of UVA Combined with Cinnamaldehyde AgainstAntioxidants (Basel, Switzerland) · 2026Article
- Staphylococcus aureus biofilm extracellular DNA neutralizes the antimicrobial activity of histone H3.NPJ biofilms and microbiomes · 2026Article
- Ecological Dynamics ofAntibiotics (Basel, Switzerland) · 2026Article
- Comparative genomics of methicillin-resistant and -susceptibleMicrobiology spectrum · 2026Article
- Ultrasound-Responsive Nanoparticles Enable Hydrophobic Antibiotic Release and Deep Penetration for Biofilm Treatment.JACS Au · 2026Article
- Biofilms in clinical infection: pathophysiology, diagnosis, and the evolving therapeutic landscape.Journal of clinical microbiology · 2026Review
- Differential sensitivity of leukocyte populations toInfection and immunity · 2026Article
- Effect ofPathogens (Basel, Switzerland) · 2026Article
- The antibacterial effectiveness of fourth-generation poly-amidoamine dendrimers-loaded with amoxicillin in combating methicillin-resistant Staphylococcus aureus.Scientific reports · 2026Article
- Effects ofAnimals : an open access journal from MDPI · 2026Article
247 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Chronic biofilm-associated infections caused by Staphylococcus aureus often lead to significant increases in morbidity and mortality, particularly when associated with indwelling medical devices. This has triggered a great deal of research attempting to understand the molecular mechanisms that control S. aureus biofilm formation and the basis for the recalcitrance of these multicellular structures to antibiotic therapy. The purpose of this review is to summarize our current understanding of S. aureus biofilm development, focusing on the description of a newly-defined, five-stage model of biofilm development and the mechanisms required for each stage. Importantly, this model includes an alternate view of the processes involved in microcolony formation in S. aureus and suggests that these structures originate as a result of stochastically regulated metabolic heterogeneity and proliferation within a maturing biofilm population, rather than a subtractive process involving the release of cell clusters from a thick, unstructured biofilm. Importantly, it is proposed that this new model of biofilm development involves the genetically programmed generation of metabolically distinct subpopulations of cells, resulting in an overall population that is better able to adapt to rapidly changing environmental conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.